On Thursday, Shares of Huntington Bancshares Incorporated (NASDAQ:HBAN), added 0.20% and closed at $10.16 in the last trading session. The last trading range of the stock ranges between $10.10 and $10.22. Huntington Bancshares Incorporated (HBAN) anticipates to report its third quarter earnings on Wednesday, October 26, 2016, before the market opening. A news release and supporting financial data will be available at that time on the company’s shareholder relations website.
NRG Energy Inc (NYSE:NRG), remained flat and closed at $10.97 in the last trading session. The last trading range of the stock ranges between $10.87 and $11.12. The company’s Market capitalization is $3.43 Billion with the total Outstanding Shares of 315.28 million. NRG Energy, Inc. (NRG) declared recently that it has begind a tender offer to purchase (the “Tender Offer”) its 7.625% senior notes due 2018 (the “2018 Notes”) for aggregate cash consideration of up to $200.0 million (the “Tender Cap”) at a purchase price determined in accordance with a modified “Dutch auction.” NRG also declared recently that it gave the required notice under the indenture governing its 7.875% senior notes due 2021 (the “2021 Notes”) to redeem for cash $192.5 million aggregate principal amount of its 2021 Notes (the “Redemption”) on November 3, 2016 (the “Redemption Date”). The redemption price for the 2021 Notes will be 103.938% of the principal amount of the 2021 Notes, plus accrued and unpaid interest to the Redemption Date. The Tender Offer and the Redemption will be financed with cash on hand.
Medtronic PLC (NYSE:MDT), lost -0.41% and closed at $85.95 in the last trading session. The last trading range of the stock ranges between $85.63 and $86.26. During the 52-week trading session the minimum price at which share price traded, registered at $69.74 and reached to max level of $89.27. DUBLIN and BARCELONA – Oct. 3, 2016 – Medtronic plc (MDT) recently declared positive clinical data for its investigational Avalus(TM) pericardial aortic surgical valve, intended for the treatment of aortic valve disease. Presented at the 30th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting for the first time, results from the PERIGON (PERIcardial SurGical AOrtic Valve ReplacemeNt) Pivotal Trial showed low rates of adverse valve-related events, high survival and improved hemodynamic performance at one year.
One of the leading, most comprehensive and modern data sets of surgical aortic valve replacement (SAVR) patients, the PERIGON Pivotal Trial is a single arm, non-randomized, prospective study of about 1,300 patients from 40 clinical sites across Europe, Canada, Japan and the United States. In the cohort presented at EACTS, outcomes of 270 patients were analyzed at the one-year endpoint. The vast majority (91 percent) of patients were at low mortality risk for open heart surgery (STS<=4 percent), with the remaining 8 percent at intermediate risk (STS=4 to 8 percent) and <1 percent at high risk (STS>=8 percent). At one year, all patients showed low rates of all-cause mortality (3.6 percent) and cardiac death (1.1 percent).